Astellas v. Haimen Pharma: Enzalutamide Patent Case Dismissed

Introduction

In a case with significant implications for pharmaceutical patent litigation, a patent infringement lawsuit filed by Astellas Pharma, Inc. against generic drug manufacturer HAIMEN PHARMA INC. was dismissed with prejudice in the U.S. District Court for the District of New Jersey. Case No. 3:24-cv-09403, resolved on January 20, 2026, after 483 days of litigation, centered on three patents protecting enzalutamide — the active ingredient in Astellas’s blockbuster prostate cancer treatment, Xtandi® (enzalutamide) tablets in 40 mg and 80 mg formulations.

The dismissal with prejudice — the most final procedural outcome short of a full trial verdict — signals a decisive resolution that forecloses Astellas from re-litigating these specific claims. For patent attorneys, IP professionals, and R&D teams operating in the pharmaceutical and oncology space, this case offers a timely window into the litigation dynamics surrounding branded drug manufacturers defending exclusivity against generic challengers under the Hatch-Waxman framework.

Case Overview

The Parties

The Patents at Issue

This landmark case involved three U.S. patents protecting enzalutamide, the active ingredient in Astellas’s blockbuster prostate cancer treatment, Xtandi®. These patents represent a layered exclusivity strategy commonly employed by branded pharmaceutical manufacturers to extend market protection.

• • U.S. Patent No. 7,709,517 B2 — a foundational compound patent in the enzalutamide portfolio
• • U.S. Patent No. 11,839,689 B2 — a later-generation patent likely covering formulation or method-of-use aspects
• • U.S. Patent No. 12,161,628 B2 — among the most recently issued patents in the cluster, potentially covering extended use or formulation refinements

Litigation Timeline & Procedural History

The complaint was filed on September 24, 2024, in the U.S. District Court for the District of New Jersey — a highly strategic venue choice. New Jersey is widely recognized as a premier jurisdiction for pharmaceutical patent litigation under the Hatch-Waxman Act, given its concentration of major drug manufacturers, experienced patent judiciary, and established procedural frameworks for ANDA (Abbreviated New Drug Application) disputes.

The case proceeded at the first-instance (district court) level and closed on January 20, 2026, spanning 483 days — approximately 16 months. This timeline is notably shorter than the average Hatch-Waxman trial, which frequently extends two to four years. The relatively compressed duration suggests the parties may have reached a negotiated resolution, or that procedural developments made continuation unnecessary or impractical before trial.

No chief judge assignment data was disclosed in the case record. The dismissal with prejudice was entered without a disclosed basis of termination in the available case data, which is consistent with a confidential settlement or a consent order between the parties.

The Verdict & Legal Analysis

Outcome

The case was dismissed with prejudice — meaning the claims were permanently extinguished and cannot be refiled in their current form. While specific damages were not awarded (consistent with a pre-trial dismissal), and no injunctive relief appears to have been formally entered by the court, the dismissal with prejudice carries significant finality. The basis of termination was not publicly disclosed in the available case record, which is common in Hatch-Waxman matters that conclude via confidential settlement agreements.

Verdict Cause Analysis

The stated cause of action was a patent infringement action, consistent with standard Hatch-Waxman litigation mechanics: a branded manufacturer files suit within 45 days of receiving notice of a Paragraph IV ANDA certification, triggering an automatic 30-month stay of FDA approval for the generic product. Within this framework, the litigation itself serves a dual function — resolving patent validity and infringement questions while also managing the FDA approval timeline for the generic challenger.

Because the case closed without a publicly available ruling on the merits, the specific legal issues adjudicated — such as claim construction, validity challenges (obviousness, anticipation, written description), or infringement findings — are not disclosed in the available case data. However, the three-patent cluster at issue suggests Haimen Pharma likely challenged at least some patents on validity grounds while contesting infringement on others, a standard Paragraph IV defense posture.

Legal Significance

The dismissal with prejudice, regardless of its underlying mechanism, has direct legal consequences: Astellas cannot reassert these specific infringement claims against Haimen Pharma for these patents and products. If the resolution was settlement-based, any licensing terms, market entry dates, or royalty arrangements would govern Haimen’s future commercialization path — terms that are almost certainly confidential.

The involvement of U.S. Patent No. 12,161,628 B2, one of the most recently issued patents in the set, is particularly notable. Late-filed continuation patents in pharmaceutical portfolios are increasingly scrutinized for double-patenting and obviousness challenges, making their assertion and ultimate resolution strategically meaningful for the broader enzalutamide patent landscape.

Strategic Takeaways

For patent holders: Layered patent portfolios combining compound, formulation, and method-of-use patents provide multiple enforcement opportunities but also multiple attack vectors. Each patent in a multi-patent assertion must be independently defensible.

For accused infringers: The relatively short litigation duration here illustrates that well-prepared generic manufacturers can drive early resolution — whether through successful IPR petitions, invalidity arguments, or negotiated entry dates — without necessarily proceeding to full trial.

For R&D teams: Freedom-to-operate (FTO) analysis must account for patent families with multiple continuation applications. A product that clears an older compound patent may still face infringement exposure from more recently issued family members.

Industry & Competitive Implications

Xtandi® (enzalutamide) is a multi-billion-dollar prostate cancer franchise, and any generic entry into the 40 mg and 80 mg tablet market carries enormous commercial stakes. The resolution of this case — regardless of its precise terms — shapes Haimen Pharma’s market entry timeline and Astellas’s ability to maintain pricing power during any remaining exclusivity period.

More broadly, this case reflects an accelerating trend in Hatch-Waxman litigation: generic manufacturers are increasingly willing to challenge even recently issued patents through a combination of ANDA litigation and parallel USPTO inter partes review (IPR) proceedings. The multi-patent assertion strategy employed by Astellas is standard for branded manufacturers protecting high-revenue assets, but it also increases litigation complexity and cost on both sides.

For companies operating in the oncology pharmaceutical space, this case reinforces several market realities: patent term extensions, pediatric exclusivity periods, and continuation patent strategies remain the primary tools for branded manufacturers defending market exclusivity, while generic challengers continue to refine their invalidity and non-infringement arguments in both district court and PTAB forums.

Licensing and settlement activity in this space — suggested here by the confidential resolution — remains a dominant outcome in Hatch-Waxman litigation, with most cases resolving before trial through negotiated market entry dates.